Understanding Voting Rights & Share Capital of Nanobiotix
Overview of Voting Rights and Share Capital in Nanobiotix
When it comes to corporate governance, understanding the voting rights and share capital of a company like Nanobiotix is essential. This information not only clarifies the company’s structure but also empowers investors and shareholders to engage meaningfully in company affairs. Let’s delve deeper into how Voting Rights and Shares Capital function within Nanobiotix, particularly as a public entity listed both on Euronext Paris and Nasdaq under the tickers Paris: NANO and Nasdaq: NBTX.
Importance of Share Capital in Corporate Structure
Share capital represents the funds that a company raises through the issuance of shares to shareholders. For Nanobiotix, this capital is crucial as it fuels the research and development of revolutionary treatments in biotechnology. The company's share capital is primarily divided among ordinary shares that entitle shareholders to vote on corporate matters during shareholder meetings.
Number of Shares Outstanding
As a publicly traded entity, Nanobiotix discloses the number of shares outstanding to inform investors of the company's equity structure. As of November 30, the company had approximately 47,426,851 shares on record. This figure is important as it directly influences the total share capital available for various corporate actions including dividends and potential stock offerings.
Voting Rights Explained
Voting rights give shareholders a voice in important decisions made by the company. The theoretical total number of voting rights for Nanobiotix is notably higher than the number of shares outstanding due to factors such as shares held in treasury, which may not carry voting rights. This distinction is essential for shareholders as it indicates how their ownership translates into influence over corporate governance.
Current Voting Rights Summary
The most recent summary of voting rights reveals that Nanobiotix exceeds 49 million total voting rights. Out of this total, the exercisable voting rights stand just below that—the latest counts show approximately 49,180,111 exercisable rights. These figures illustrate the significant level of engagement that shareholders can exert in decisions affecting the company.
About NANOBIOTIX
Founded in 2003 and headquartered in Paris, France, Nanobiotix is a pioneering firm in the field of biotechnology. The heart of this company thrives on innovative approaches that engage physics to enhance treatment outcomes for cancer patients globally. With a profound commitment to making a positive impact on humanity’s health, Nanobiotix is set apart by its unique portfolio of more than 25 patent families encompassing several promising nanotechnology platforms.
A Global Presence
In addition to its Paris headquarters, Nanobiotix has expanded its reach globally, most notably with a presence in Cambridge, Massachusetts, USA. This international footprint allows the company to collaborate with various leading research institutions and keeps it in touch with a broader market.
Commitment to Innovation
Nanobiotix stands at the forefront of developing groundbreaking therapies in oncology and other critical health areas. Its multi-faceted approach integrates nanotechnology across its offerings, pushing the boundaries of treatment possibilities. With ongoing clinical trials aimed at improving the quality of life for patients, the company continually invests in research and partnerships to advance its mission.
Contact Information for Stakeholders
For shareholders, stakeholders, or anyone interested in engaging with Nanobiotix, key contact details are readily available. The communications department can be approached through Brandon Owens, VP of Communications, at +1 (617) 852-4835.
For investor relations, Craig West serves as the SVP and can be contacted at +1 (617) 583-0211. Both departments can facilitate queries about voting rights, share capital, and any other shareholder-related information.
Frequently Asked Questions
What are voting rights in relation to shares?
Voting rights refer to the entitlement of shareholders to vote on certain company matters, notably during annual shareholder meetings and other significant corporate decisions.
How does voting power affect shareholder influence?
Voting power directly correlates to a shareholder's ability to influence company management and policies, making understanding voting rights crucial for investors.
What is the significance of share capital for a company?
Share capital is crucial as it provides necessary funds for a company to operate, invest, and grow. It also reflects the company’s financial health and investor confidence.
How many voting rights does Nanobiotix currently hold?
As of the latest update, Nanobiotix holds approximately 49,202,229 total voting rights, showcasing robust stakeholder engagement.
Who can I contact for more information regarding Nanobiotix investments?
The investor relations department at Nanobiotix, led by Craig West, is available for inquiries related to investments and corporate governance.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.